PPT-Dabigatran in myocardial injury after noncardiac

surgery Dr PJ Devereaux on behalf of MANAGE Investigators Population Health Research Institute Hamilton Canada Background MINS includes MI and isolated ischemic troponin elevation that occur within first 30 days after surgery . Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. Susana G. Garcia MD. No Disclosure. Objectives. Review the current definition, risk factors, clinical impact and incidence of PMI. Describe the different clinical presentation of PMI and how this dictate the goal and approach to diagnosis and treatment of PMI. . MI = . heart attack. Defined as necrosis of heart muscle resulting from ischemia.. . A very significant cause of death worldwide. . of these deaths, 33% -50% die before they can reach the hospital. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. Byron Rudman 14019991. Brandon Wright 14015570. Brenton . Lotz. 14008442. Emilio . Guerro. 13140346. Kyle . Rorke. 13415591. Myocardial Infarction. Definition: Myocardial Infarction occurs when the heart is subject to prolonged exposure to ischemia, resulting in irreversible necrosis of the myocardium.. Fawaz Altuwaijri. ACEM trainee. Introduction. Characteristics . of novel . anticoagulants. Laboratory Testing. Reversal in the bleeding patient. Introduction. Prevalence . atrial fibrillation. . 3.03 million in 2005. VIABILITY. CORONARY ARTERY DISEASE. ACUTE CORONARY SYNDROME. Undergo . revascularisation. procedures. . Improved survival. Increased number of patients with residual LV dysfunction undergoing progressive LV remodeling and congestive heart failure. Allyson Sarigianis, Pharm.D.. October 19, 2013. Objectives. Review current practice recommendations for prevention of stroke/systemic embolism in atrial fibrillation. Compare and contrast pharmacology between warfarin and target specific oral anticoagulants (TSOACs). hypoperfusion. . The presence of glucose activity by FDG imaging provides evidence of viability beyond perfusion by either PET or SPECT.” . 7. PET for the Evaluation of Myocardial . Viability. Add presenter info here. hypoperfusion. . The presence of glucose activity by FDG imaging provides evidence of viability beyond perfusion by either PET or SPECT.” . 7. PET for the Evaluation of Myocardial . Viability. Add presenter info here. infarction (STEMI). The basics. Epidemiology. Pathophysiology. Symptoms & diagnosis. Content. Epidemiology. Epidemiology. Pathophysiology. Symptoms & diagnosis. 4. CVD is a major cause of death worldwide. PROF. & H.O.D.. PM. Myocardial Infarction if the rapid development of myocardial necrosis by a critical imbalance between oxygen supply and demand to the myocardium. Background. Acute coronary syndromes include. NOAC vs Warfarin Atrial Fibrillation Studies – Asian representation. RE-LY. ROCKET. ARISTOTLE. ENGAGE. Drug. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. Class. DTI. Anti-. Xa. Anti-. Xa. Anti-. Xa. Dr. PJ Devereaux on behalf of POISE-3. Investigators. Population Health Research Institute, Hamilton, Canada. Funding: Canadian Institutes of Health Research, . National Health and Medical Research Council (Australia), Research Grant Council (Hong...